Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Travere Therapeutics (NASDAQ: TVTX).The analyst commented, "Filspari got full approval ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments